Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Phase 2 Completed 45 enrolled Swiss Cancer Institute

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with liver cancer that cannot be removed by surgery.

Timeline

Start: 2007-07
Primary completion: 2008-08
Completion: 2009-02

Outcome

Met primary endpoint

paper PFS12 was rated successful in 15 patients (33%; 95% confidence interval, 20%-47%). PMID 20203173 ↗

Publications

Results Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovacs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	37.5 mg	Oral